Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial

Significant benefit was observed in 78% of the 188 patients with fibromyalgia who completed the trial.

• Both dosages of sodium oxybate (4.5 gm and 6 gm) led to improvements in symptoms of fibromyalgia.
• The primary outcome variable showed a greater than 20% improvement in pain and impact scores for many patients.
• Improvements in pain levels were significantly associated with better sleep quality.
• Sodium oxybate was generally well tolerated, with nausea and dizziness occurring in 28% and 18% of patients, respectively, but these effects often resolved with continued use.

AI simplified